Genetic Analyst and Molecular Biologist with extensive expertise in somatic genetic analysis, oncology, and molecular diagnostics, seeking to leverage my background in a commercial setting within the pharmaceutical or biotech industry. Demonstrated ability to apply advanced genetic techniques, including Next-Generation Sequencing (NGS) and Sanger sequencing, to the analysis and categorization of oncogenic variants. Proven track record in designing and executing research projects, managing biobank operations, and delivering precise molecular reports for clinical application. Adept at translating complex scientific insights into actionable clinical data, with a strong focus on personalized medicine and supporting therapeutic decision-making processes.
Genetic Analysis & Molecular Diagnostics: Expertise in NGS (TruSight Oncology 500, Oncomine Comprehensive Assay) and Sanger sequencing for the identification, interpretation, and categorization of oncogenic variants in somatic mutations
Oncology & Personalized Medicine: Specialized in multiple oncology indications, including colorectal cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), cholangiocarcinoma, and gastrointestinal stromal tumors (GIST) Experience in producing detailed molecular reports that support personalized treatment strategies
Clinical & Research Expertise: Proven experience in both academic and clinical research environments, including clinical trials, with a focus on translating research findings into clinical application
Cross-functional Collaboration: Experienced in working within multidisciplinary teams, bridging the gap between research, clinical needs, and commercial goals Strong communication skills, adaptable to corporate environments, and client-focused
MS Excel
Documentation And Reporting
Report Preparation
Excel proficiency
Root Cause Analysis
Team Collaboration and Leadership
Analytical Thinking
Ph.D. in Molecular Medicine with honors, specializing in oncology and precision medicine. Developed an innovative glioblastoma model and created the MuNSC cell line, later acquired by Applied Biological Materials Inc. Published 14 articles in JCR journals (50% as first author). Extensive experience in biomarker research, precision oncology (NSCLC), and NIH-funded Alzheimer's projects. Skilled in leading research teams, managing clinical trial samples, and contributing to translational research initiatives. Currently focused on enhancing precision oncology strategies through a European-funded postdoctoral project.
BaseSpace
Torrent Suite
FASTQC
Animal experimentation training course